- Forma Life Sciences has launched as an independent CDMO focused on oral solid dosage formulation development, clinical manufacturing, and commercial drug product manufacturing in the United States.
- The company operates two GMP facilities in Irvine, California totaling more than 100,000 square feet with capacity to produce over two billion tablets and capsules annually.
Forma Life Sciences has launched as an independent contract development and manufacturing organization (CDMO) focused on oral solid dosage formulation development, clinical manufacturing, and commercial drug product production in the United States. The company began operations in January 2026 and is headquartered in Irvine, California.
The CDMO was established following BioSelective Capital Investments’ acquisition of the U.S. drug product development and manufacturing operations of BioDuro. The transaction included two established GMP facilities in Irvine with regulatory experience supporting clinical and commercial oral solid dosage programs.
Forma operates two cGMP-compliant sites totaling more than 100,000 square feet and housing 27 GMP manufacturing suites. The facilities support oral solid dosage formulation development, Phase I–III clinical manufacturing, process scale-up, technical transfer, and commercial drug product manufacturing. The platform has the capacity to produce more than two billion tablet and capsule units per year as part of its contract manufacturing services.
“For more than 30 years, this organization has supported the pharmaceutical supply chain. Forma was created to preserve that operating foundation while building a focused U.S. based CDMO platform designed for disciplined execution and long-term partnership.”
Cyrus Mirsaidi, Executive Chairman and Chief Executive Officer of Forma Life Sciences
The company provides formulation development and manufacturing services for tablets and capsules from early clinical development through commercial supply. According to Forma, its technical capabilities include spray-dried dispersion for amorphous solid dispersion systems and commercial-scale fluid bed granulation and coating technologies used in modified-release and multiparticulate dosage forms.
